Last reviewed · How we verify

Januvia (sitagliptin)

Zealand University Hospital · FDA-approved active Small molecule

Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), which increases levels of incretin hormones that stimulate insulin secretion in response to glucose.

Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), which increases levels of incretin hormones that stimulate insulin secretion in response to glucose. Used for Type 2 diabetes mellitus.

At a glance

Generic nameJanuvia (sitagliptin)
Also known asJanuvia
SponsorZealand University Hospital
Drug classDPP-4 inhibitor
TargetDPP-4 (dipeptidyl peptidase-4)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

By blocking DPP-4 enzyme activity, sitagliptin prevents the degradation of GLP-1 and GIP, two incretin hormones that enhance glucose-dependent insulin secretion and suppress glucagon release. This mechanism leads to improved glycemic control in type 2 diabetes patients, particularly in the postprandial period, without causing hypoglycemia when used as monotherapy.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results